Neda Nikpoor, MD
Ophthalmology · Honolulu, HINPI 1598024077
Payments from drug & device makers
Across 629 payments — averaging $511.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$101K
- AbbVie$55K
- Lensar, Inc.$30K
- Sun Pharmaceutical Industries Inc.$24K
- Alcon$24K
- Johnson & Johnson Surgical Vision, Inc.$21K
- plus $67K from 26 others
What the payments were for
- Consulting fees$148,83551%
- Speaking & faculty fees$79,78127%
- Travel & lodging$21,2537%
- Food & beverage$41,16014%
- Education$70%
- Gifts$1,6251%
- Other$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 44 | $101,338 |
| AbbVie(2 entities) | 92 | $54,665 |
| Lensar, Inc. | 19 | $30,268 |
| Sun Pharmaceutical Industries Inc. | 55 | $23,883 |
| Alcon | 79 | $23,500 |
| Johnson & Johnson Surgical Vision, Inc. | 34 | $21,092 |
| Bausch & Lomb Americas Inc. | 60 | $18,790 |
| Ziemer USA | 11 | $12,878 |
| Glaukos Corporation | 30 | $9,303 |
| Dompe US, Inc. | 35 | $6,714 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 22 | $4,487 |
| Sight Sciences, Inc. | 47 | $3,487 |
| Tarsus Pharmaceuticals, Inc. | 15 | $2,793 |
| Oyster Point Pharma, Inc. | 11 | $2,646 |
| Kala Pharmaceuticals, Inc. | 13 | $1,567 |
| Beaver-visitec International, Inc. | 3 | $1,058 |
| Alcon Research LLC | 2 | $808 |
| Novartis | 26 | $760 |
| Biotissue Holdings Inc. | 4 | $683 |
| Amgen(2 entities) | 8 | $386 |
| Ivantis, Inc | 2 | $229 |
| Aerie Pharmaceuticals, Inc. | 2 | $157 |
| Carl Zeiss Meditec USA, Inc. | 1 | $80 |
| Carl Zeiss Meditec, Inc. | 1 | $65 |
| Lumibird Medical Inc. | 1 | $58 |
| Harrow Eye, LLC | 2 | $56 |
| Staar Surgical Company | 3 | $56 |
| Shire North American Group Inc | 1 | $40 |
| Eyevance Pharmaceuticals LLC | 2 | $35 |
| Eyepoint US, Inc. | 1 | $33 |
| Mallinckrodt Hospital Products Inc. | 2 | $27 |
| Welch Allyn | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$63,294
- RXSIGHT INJECTOR CARTRIDGE$63,294
- RXSIGHT INJECTOR HANDPIECE$63,294
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$63,294
- LIGHT ADJUSTABLE LENS (LAL)$50,862
- VUITY$46,552
- LENSAR LASER SYSTEM$30,117
- CEQUA$22,854
- Catalys Laser System$15,238
- Tecnis Multifocal Family of 1-piece IOLS$15,238
- COMPACT INTUITIV Phacofragmentation System$15,238
- Healon Viscoelastics$15,238
- MIEBO$14,674
- XIIDRA$13,675
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$13,084
- Z8$12,595
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$12,432
- Oxervate$6,041
- Wavelight Refractive Suite$4,754
- Clareon$4,470
How this compares
$321,963 in reported general payments places this provider in the 95th percentile of 120 ophthalmology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lotemax SmLoteprednol Etabonate | 79 | $19,610 |
| BesivanceBesifloxacin Hcl | 77 | $16,994 |
| ProlensaBromfenac Sodium | 44 | $15,074 |
| Bromfenac Sodium | 28 | $6,785 |
| MoxifloxacinMoxifloxacin Hcl | 31 | $1,212 |
| Prednisolone Acetate | 27 | $829 |
| ValacyclovirValacyclovir Hcl | 17 | $565 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Besivance, Prolensa | $4,487 | $51,679200 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 120 ophthalmology providers in Hawaii.
Other ophthalmology in Honolulu
- Carlton YuenHonolulu$440K
- Alan FaulknerHonolulu$207K
- Michael BennettHonolulu$190K
- Jeffrey PetersonHonolulu$85K
- Rupa WongHonolulu$72K
- Worldster LeeHonolulu$30K
- Elysse TomHonolulu$20K
- Jon PortisHonolulu$20K
- Tyrie JenkinsHonolulu$19K
- John OlkowskiHonolulu$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.